Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?

Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque

(2015) Josa M. Frischer et al.   ANNALS OF NEUROLOGY

Treatment withdrawal in relapsing−remitting multiple sclerosis: a retrospective cohort study

(2015) G. Lus et al.   EUROPEAN JOURNAL OF NEUROLOGY

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

(2015) D. M. Hartung et al.   NEUROLOGY

Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data

(2014) Cathryn A Carroll et al.   BMC HEALTH SERVICES RESEARCH

Relapses and disability accumulation in progressive multiple sclerosis

(2014) M. M. Paz Soldan et al.   NEUROLOGY

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis

(2013) Anthony T. Reder et al.   Multiple Sclerosis and Related Disorders

Rebound of Disease Activity After Withdrawal of Fingolimod (FTY720) Treatment

(2012) Joachim B. Havla   ARCHIVES OF NEUROLOGY

Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients

(2011) A. Kerbrat et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

(2010) Antonio Scalfari et al.   BRAIN

Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?

(2009) Roisín Lonergan et al.   Multiple Sclerosis Journal

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

(2008) L. K. Fisniku et al.   BRAIN